APA (7th ed.) Citation

JR, T., CL, H., HH, H., KC, H., CY, W., KH, L., . . . CC, W. (2026). Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: A preclinical theranostic study targeting fibroblast activation protein. EJNMMI research, 16(1), . https://doi.org/10.1186/s13550-026-01405-z

Chicago Style (17th ed.) Citation

JR, Tseng, Hsu CL, Hsieh HH, Ho KC, Wu CY, Lin KH, Chung YH, and Weng CC. "Combined Antitumor Activity of [177Lu]Lu-FAPI-2286 and Pazopanib in a Sarcoma Model: A Preclinical Theranostic Study Targeting Fibroblast Activation Protein." EJNMMI Research 16, no. 1 (2026). https://doi.org/10.1186/s13550-026-01405-z.

MLA (9th ed.) Citation

JR, Tseng, et al. "Combined Antitumor Activity of [177Lu]Lu-FAPI-2286 and Pazopanib in a Sarcoma Model: A Preclinical Theranostic Study Targeting Fibroblast Activation Protein." EJNMMI Research, vol. 16, no. 1, 2026, https://doi.org/10.1186/s13550-026-01405-z.